Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis [0.03%]
在化疗的第一天使用培非格司亭合理吗？一种成本效用分析
Caroline C Billingsley,David E Cohn,Aleia K Crim et al.
Caroline C Billingsley et al.
Background: There is recent evidence supporting the safety and efficacy of same-day dosing of pegfilgrastim in patients undergoing chemotherapy. Objective...
Ductal carcinoma in situ of the breast - Long term results from a twenty-year cohort [0.03%]
乳腺导管原位癌的长期疗效分析——20年随访结果
Michael Co,Ava Kwong
Michael Co
Introduction: Long-term survival is excellent in ductal Carcinoma in situ (DCIS); whether or not we are over-treating DCIS has been a major public concern. This study aims at reviewing the long-term survival outcome of DC...
Sirisha Pemmaraju,Lingaiah Amidyala,Ravindra Vottery et al.
Sirisha Pemmaraju et al.
Background: Ovarian cancer is the most common cancer among women worldwide. Estrogen plays an important role in follicle formation and maturation of oocyte via its receptor (ER). It has a special interest as their protein...
Diagnosis of lung tumor types based on metabolomic profiles in lymph node aspirates [0.03%]
基于代谢组谱系的肺癌类型诊断
Daniel Sappington,Scott Helms,Eric Siegel et al.
Daniel Sappington et al.
Background: Treatment of lung cancer is evolving from the use of cytotoxic drugs to drugs that interrupt pathways specific to a malignancy. The field of metabolomics has promise with respect to identification of tumor-spe...
LIFETIME PHYSICAL INACTIVITY IS ASSOCIATED WITH LUNG CANCER RISK AND MORTALITY [0.03%]
终生缺乏体育锻炼与肺癌的风险和死亡率有关
Rikki Cannioto,John Lewis Etter,Michael J LaMonte et al.
Rikki Cannioto et al.
Introduction: Investigations of the independent associations of physical inactivity with cancer endpoints have been mounting in the epidemiological literature, in part due to the high prevalence of physical inactivity amo...
Adriana Zingone,Derek Brown,Elise D Bowman et al.
Adriana Zingone et al.
Objectives: In recent years, the anti-cancer properties of several commonly used drugs have been explored, with drugs such as aspirin and beta-blockers associated with improved cancer outcomes. Previous preclinical work d...
Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy [0.03%]
剂量递增二期研究：继接受抗血管内皮生长因子治疗后病情恶化的患者再次使用多替尼治疗
Thomas J Semrad,Edward J Kim,Michael S Tanaka et al.
Thomas J Semrad et al.
Background: Prior work identified the fibroblast growth factor (FGF) pathway as a mediator of resistance to anti-vascular endothelial growth factor (VEGF) therapy. We tested dovitinib, an inhibitor of both FGF and VEGF re...
TELEHEALTH ALLOWS FOR CLINICAL TRIAL PARTICIPATION AND MULTIMODALITY THERAPY IN A RURAL PATIENT WITH STAGE 4 NON-SMALL CELL LUNG CANCER [0.03%]
远程医疗使农村地区的晚期非小细胞肺癌患者能够参与临床试验和多模式治疗
James M Clark,Laurence J Heifetz,Daphne Palmer et al.
James M Clark et al.
Oligometastatic non-small cell lung cancer (NSCLC) has a poor prognosis for rural patients with traditional therapies. Implementation of multi-modality systemic therapy in conjunction with surgical resection can dramatically improve overall...
Effect of trilaciclib administered before chemotherapy in patients with extensive-stage small-cell lung cancer: A pooled analysis of four randomized studies [0.03%]
一种化疗前使用的三药脂氯-libium治疗广泛期小细胞肺癌患者的疗效：四项随机研究的汇总分析
Background: Trilaciclib is a transient cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that reduces the incidence of chemotherapy-induced myelosuppression (CIM). In this pooled analysis, we evaluated the multilineage myelo...
The role of dietary sugars in cancer risk: A comprehensive review of current evidence [0.03%]
膳食糖与癌症风险的关系：现有证据的全面回顾
Goal of the review: The objective of this review is to conduct a thorough examination of the current evidence regarding the correlation between dietary sugar intake and cancer risk. This will encompass the biological mech...